title: The risks and benefits of indacaterol--the FDA's review.
authors.affiliation: Division of Pulmonary, Allergy, and Rheumatology Products, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
authors.forename: Badrul A
authors.initials: BA
authors.lastname: Chowdhury
authors.forename: Sally M
authors.initials: SM
authors.lastname: Seymour
authors.forename: Theresa M
authors.initials: TM
authors.lastname: Michele
authors.forename: Anthony G
authors.initials: AG
authors.lastname: Durmowicz
authors.forename: Dongmei
authors.initials: D
authors.lastname: Liu
authors.forename: Curtis J
authors.initials: CJ
authors.lastname: Rosebraugh
mesh_terms: D000280:Administration, Inhalation; D058672:Adrenergic beta-2 Receptor Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D001249:Asthma / Q000139:chemically induced / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D017277:Drug Approval; D004341:Drug Evaluation / Q000379:methods; D006801:Humans; D007189:Indans / Q000008:administration & dosage* / Q000009:adverse effects; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy; D015363:Quinolones / Q000008:administration & dosage* / Q000009:adverse effects; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D058672:Adrenergic beta-2 Receptor Antagonists; D007189:Indans; D015363:Quinolones; C510790:indacaterol